Project Grant R21DA065026
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Pittsburgh $493,454 under the Drug Use and Addiction Research Programs (CFDA 93.279) for a two-year project period (September 1, 2025 – August 31, 2027) to conduct research on the effects of xylazine exposure on maternal, perinatal, and infant outcomes. The research addresses a critical public health issue, as overdose deaths among pregnant women who use drugs (PWWUD) account for...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a Project Grant totaling $193,854 under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period September 1, 2025, through August 31, 2027. The award funds an epidemiological cohort study examining the association between xylazine use and adverse health outcomes among people who have injected drugs in the Baltimore area. The study will leverage the existing ALIVE...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Washington University a Project Grant totaling $466,500.00 under the Drug Use and Addiction Research Programs (CFDA 93.279) effective June 15, 2025, with a completion date of May 31, 2027. This research project addresses the emerging public health threat of xylazine contamination in the illicit drug supply and associated invasive infections. The primary deliverables include active surveillance of the local...
- Federal Grant Award Summary Thomas Jefferson University received a $600,000 Project Grant from the Health Resources and Services Administration (HRSA) under the Mental and Behavioral Health Education and Training Grants program (CFDA 93.732), effective July 1, 2025, through June 30, 2030. The award supports the expansion of Thomas Jefferson University's Addiction Medicine and Addiction Psychiatry Fellowship programs to address the critical shortage of trained addiction specialists in the...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Scripps Research Institute a $506,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning July 15, 2025, through June 30, 2027. The award supports research focused on the preparation and investigation of monoclonal antibodies designed to block xylazine's mechanism of action and mitigate its adverse effects. Xylazine, a veterinary sedative increasingly detected as an adulterant...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $196,020 Project Grant (K23 career development award) to the University of Pennsylvania effective September 1, 2025, through August 31, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports Dr. Eleanor Turi, PhD, RN, CCRN in conducting mentored research training to identify low-barrier wound care models associated with positive patient outcomes among people who inject drugs...
- Federal Grant Award Summary Yale University received a $197,024 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) effective July 30, 2025, through June 30, 2027. This award supports a two-state research initiative examining the impact of xylazine, a veterinary tranquilizer increasingly present in the unregulated opioid supply, on people who use drugs (PWUD). The project delivers comprehensive research services...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a K23 Career Development Grant totaling $195,428 to Dr. Jennifer Love at Icahn School of Medicine at Mount Sinai on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research focused on improving emergency department (ED) care for patients with opioid use disorder (OUD) exposed to xylazine and novel adulterants. Dr. Love will develop and operate a clinical...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a $722,917 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning September 15, 2025, with an ultimate completion date of May 31, 2030. This research project evaluates a novel approach to dispensing methadone in carceral facilities by leveraging the 2024 Substance Abuse and Mental Health Services Administration final rule clarifying that facilities...
- Federal Project Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $534,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective September 1, 2025, through May 31, 2030. This research initiative investigates the lifespan effects of prenatal and perinatal opioid exposure on the brain's metabolic-epigenetic axis. The project employs innovative methodologies including...
Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $346,500 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning February 15, 2026, with a completion date of January 31, 2028. The award supports research addressing the intersection of xylazine contamination in the opioid supply and pregnancy outcomes for women who use opioids (PWUO). The project generates evidence-based data on how xylazine has complicated prenatal care access and entry into treatment for opioid use disorder, with particular attention to the unique vulnerabilities of pregnant populations affected by substance use and the rapid geographic expansion of xylazine prevalence across all U.S. census regions. This research initiative directly addresses critical gaps in medical knowledge regarding xylazine's effects on pregnancy and peripartum care. By investigating barriers to care access, treatment engagement, and clinical outcomes among PWUO in the context of xylazine contamination, the project contributes to NIDA's mission to develop prevention, diagnosis, and treatment approaches for substance use disorders and related health complications. The work is conducted at Thomas Jefferson University's facilities in Philadelphia, Pennsylvania, a region experiencing particularly acute xylazine prevalence in opioid-dependent populations.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $346.5k | 2/12/26 |